Navigation Links
Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
Date:9/12/2008

SYDNEY, Australia, Sept. 12 /PRNewswire/ -- Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, today announced that it has received conditional approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its first U.S. clinical feasibility trial for the C-Pulse(TM) device in patients with moderate heart failure. C-Pulse is an implantable aortic cuff, designed as a cost effective heart assist therapy. The device is a uniquely positioned Class III heart failure therapy that offers an innovative intervention bridging the clinical gap between heart failure pacemakers and end stage therapies which potentially creates a new market opportunity.

Enrollment is expected to begin at six premiere U.S. medical institutions by the end of 2008. The objective of the trial is to evaluate the safety and efficacy of C-Pulse in 20 patients currently suffering from moderate heart failure. William Abraham, MD, of Ohio State University, and Patrick McCarthy, MD, of Northwestern University Medical Center, will serve as national co-lead principal investigators. Each patient's performance with C-Pulse will be closely monitored over a six month follow-up period.

Following the trial's successful completion, the Company will request CE Mark approval to market C-Pulse in the E.U. and other international countries that honor CE Mark label claims for device safety. In addition, the Company will seek FDA approval for a larger randomized U.S. pivotal study to support the submission of a marketing application for C-Pulse in the U.S.

Malcolm McComas, Chairman of the Board commented, "We are proud to announce that Sunshine Heart is the first company to receive FDA approval to run a clinical trial evaluating a non-blood contacting heart assist device. The agency's clinical approval of this treatment approach for moderate heart failure raises Sunshine Heart's profile as a global development stage medical device company supported by internationally renowned trial centers and lead investigators."

Donald Rohrbaugh, Chief Executive Officer, said, "We are very encouraged by the FDA's IDE approval for C-Pulse and look forward to generating additional data from this study to support our global regulatory strategy. Our C-Pulse heart assist therapy offers a unique treatment to patients who are suffering from moderate heart failure and represents an important advancement in addressing this significant unmet clinical need. If left untreated, moderate heart failure is a debilitating disease that can lead to premature death. We believe that C-Pulse represents one of the most innovative therapies in development for this indication in patients who no longer receive symptom relief from medication or cardiac synchronization pacemakers. With more than five million people suffering from heart failure today and a half million more diagnosed each year, we are extremely confident in the advantages C-Pulse provides to patients as a simple, safe, less invasive, non-blood contacting implant option."

About Sunshine Heart

Sunshine Heart (ASX: SHC) (http://www.sunshineheart.com) is a global medical device company, committed to the commercialization of C-Pulse(TM) an implantable, non-blood contacting, heart assist therapy for the treatment of people with heart failure. Through the use of counterpulsation technology, C-Pulse(TM) is designed to increase cardiac output while reducing the heart's workload for ventricular loading. Sunshine Heart listed on the ASX in September 2004 has a presence in Australia, New Zealand and the United States of America.

For further information, please visit http://www.sunshineheart.com or contact:

Sunshine Heart: Investor Relations:

Don Rohrbaugh R.J. Pellegrino

Chief Executive Officer The Ruth Group

+1 714 259 0732 646-536-7009

don.rohrbaugh@sunshineheart.com rpellegrino@theruthgroup.com

Media:

Janine McCargo

The Ruth Group

646-536-7033

jmccargo@theruthgroup.com

Forward Looking Statements

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company's filings with the Australian Securities Exchange.


'/>"/>
SOURCE Sunshine Heart
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Many Heart Attack Patients Dont Get Best Emergency Treatment
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and PUNE, India , January ... by Allied Market Research, titled, "Breast Imaging Technologies Market by ... the global breast imaging technologies market size was valued at ... million by 2022, growing at a CAGR of 8.4% from ... Europe together accounted for over three-fourths ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... de 2017  Hoy, en el Foro Económico Mundial, ... global para avanzar el acceso a la prevención de ... renta baja y baja-media (LICs y LMICs). ... particularmente en países de renta baja y media, donde ... muertes relacionadas con NCD. El objetivo de Access Accelerated, ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Dr. Andrew Lian-Jie Li ... trained Mohs and cosmetic surgeon. After extensive dermatology research training at the National ... in internal medicine at the Emory University and dermatology training at the University ...
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. ... a modern CTMS workflow designed to seamlessly integrate and streamline the way researchers ... a single page, maximizing usability and improving efficiency significantly for users – a ...
(Date:1/19/2017)... Antonio, Texas (PRWEB) , ... January 19, 2017 , ... ... the GenCure Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship ... accounts. The competition begins Feb. 1, and the deadline is May 31, with the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics ... , The Tranquility privacy panel system was designed to deliver the ideal ... help reduce noise and provide the visual privacy required to maintain concentration levels ...
(Date:1/19/2017)... Pittsburgh, PA (PRWEB) , ... January 19, 2017 , ... ... the experience of patients who seek access to the Network’s programs and services in ... requesting primary or specialty care appointments will be offered one for that same afternoon. ...
Breaking Medicine News(10 mins):